Target Name: TINCR
NCBI ID: G257000
Review Report on TINCR Target / Biomarker Content of Review Report on TINCR Target / Biomarker
TINCR
Other Name(s): TUBL | TINCR ubiquitin domain containing | tissue differentiation-inducing non-protein coding RNA | placenta-specific 2 (non-protein coding) | TINCR-encoded ubiquitin-like protein | onco-lncRNA-16 | PLAC2 | LINC00036 | NCRNA00036 | long intergenic non-protein coding RNA 36 | terminal differentiation-induced ncRNA

TINCR: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Introduction

Inflammatory neurodegenerative diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and chronic progressive diffuse photoneuropathy (CPD), are characterized by the progressive damage of the central nervous system (CNS) and can lead to a range of symptoms, including muscle weakness, paralysis, and cognitive impairments. These conditions are often treated with immunomodulatory drugs, which aim to reduce inflammation in the CNS. However, these drugs can have a limited impact on the treatment of these diseases, and there is a need for new and more effective treatments.

TINCR: A Novel Drug Target and Biomarker

TINCR (TUBL), a small molecule inhibitor of the nuclear factor kappa B (NF-kappa-B), has been shown to have a great potential in the treatment of inflammatory neurodegenerative diseases. NF-kappa-B is a protein that plays a crucial role in the regulation of inflammation and has been implicated in the development and progression of many inflammatory neurodegenerative diseases.

In the case of MS, NF-kappa-B has been shown to be involved in the regulation of immune cells that infiltrate the CNS and contribute to the development of the disease. Similarly, in ALS, NF-kappa-B has been implicated in the regulation of motor neuron function and has been shown to be involved in the development of the disease.

TINCR works by inhibiting the activity of NF-kappa-B, which can reduce the inflammation in the CNS and potentially slow the progression of these diseases. Studies have shown that TINCR can be effective in animal models of MS and ALS, and it is now being tested in clinical trials.

TINCR is also a potential biomarker for the diagnosis and monitoring of inflammatory neurodegenerative diseases. The ability to measure the level of NF-kappa-B activity in the CNS can be used as an indicator of the level of inflammation and the effectiveness of TINCR treatment. This can be a valuable diagnostic tool for monitoring the progression of these diseases and could potentially aid in the selection of patients for targeted therapies.

Conclusion

In conclusion, TINCR is a promising drug target and biomarker for the treatment of inflammatory neurodegenerative diseases. Its ability to inhibit the activity of NF-kappa-B and its potential as a clinical trial candidate make it an attractive candidate for further research. As the field of neurodegenerative diseases continue to evolve, the development of new and effective treatments will be critical to the treatment of these conditions.

Protein Name: TINCR Ubiquitin Domain Containing

The "TINCR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TINCR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TINF2 | TIPARP | TIPARP-AS1 | TIPIN | TIPRL | TIRAP | TIRAP-AS1 | TJAP1 | TJP1 | TJP2 | TJP3 | TK1 | TK2 | TKFC | TKT | TKTL1 | TKTL2 | TLCD1 | TLCD2 | TLCD3A | TLCD3B | TLCD4 | TLCD4-RWDD3 | TLCD5 | TLDC2 | TLE1 | TLE1-DT | TLE2 | TLE3 | TLE4 | TLE5 | TLE6 | TLK1 | TLK2 | TLL1 | TLL2 | TLN1 | TLN2 | TLNRD1 | TLR1 | TLR10 | TLR12P | TLR2 | TLR3 | TLR4 | TLR5 | TLR6 | TLR7 | TLR8 | TLR8-AS1 | TLR9 | TLX1 | TLX1NB | TLX2 | TLX3 | TM2D1 | TM2D2 | TM2D3 | TM4SF1 | TM4SF1-AS1 | TM4SF18 | TM4SF19 | TM4SF19-AS1 | TM4SF19-DYNLT2B | TM4SF20 | TM4SF4 | TM4SF5 | TM6SF1 | TM6SF2 | TM7SF2 | TM7SF3 | TM9SF1 | TM9SF2 | TM9SF3 | TM9SF4 | TMA16 | TMA7 | TMBIM1 | TMBIM4 | TMBIM6 | TMC1 | TMC2 | TMC3 | TMC4 | TMC5 | TMC6 | TMC7 | TMC8 | TMCC1 | TMCC1-DT | TMCC2 | TMCC3 | TMCO1 | TMCO1-AS1 | TMCO2 | TMCO3 | TMCO4 | TMCO5A | TMCO5B | TMCO6